Sungho Bea/LinkedIn
Aug 2, 2025, 17:34
Oral Anticoagulation in VTE: Apixaban Safer and More Effective than Rivaroxaban or Warfarin
The Heart has published on X:
“Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Apixaban was asso with a lower risk of recurrent VTE and major bleeding compared to rivaroxaban and warfarin in pts initiating oral anticoagulant therapy.”
Title: Oral Anticoagulation and Risk of Adverse Clinical Outcomes in Venous Thromboembolism
Authors: Sungho Bea, PharmD, PhD; Geetha S. Iyer, PhD; Dae Hyun Kim, MD, MPH, ScD; Kueiyu Joshua Lin, MD, ScD, MPH; Yichi Zhang, MS; Heidi Zakoul, BS; Helen Tesfaye, PharmD, MSc; Katsiaryna Bykov, PharmD, ScD
Read the full article here.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events
-
Nov 8, 2026, 14:05Kausik Ray: Plaque-Guided Care for Better Coronary Outcomes
-
Nov 8, 2026, 14:05Athira Elssa Johnson: Understanding Coronary Thrombosis and Its Risks
-
Nov 8, 2026, 14:04Sanjiv Beri: Blood Type Compatibility and the Balance of Giving and Receiving
-
Nov 8, 2026, 14:02Gabriela Hobbs: Recognizing Outstanding Abstract Achievements-ASH 2026
-
Nov 8, 2026, 12:22Marc Carrier: Advancing Catheter-Related Thrombosis Prevention Through Factor XI Inhibition
-
Nov 8, 2026, 11:56Why Genetic Predisposition Does Not Always Lead to Thrombosis – Stork Genetics